Some of the organs in the body do not have to be in their current location, nor structured in a single mass of tissue, in order to carry out all of their functions. The liver is one of these organs. Many (not all, but many) of the functions of the liver could be carried out by small amounts of liver tissue distributed throughout the body. Thus the existence of companies like Lygenesis, shepherding clinical trials of liver tissue organoid transplantation into lymph nodes to help restore lost function. Here, researchers report on the early stages of development for an alternative approach that is even less like normal liver tissue, essentially just an injection of cells and hydrogel rather than any production of structured tissue for transplantation, but that nonetheless produces a small volume of pseudo-tissue at the injection site that can carry out many of the functions of the liver.
Liver transplantation remains the standard treatment for end-stage liver failure, yet it is limited by donor scarcity, surgical complexity, and poor accessibility. Cell-based therapies offer an alternative, yet their translation has been hindered by low engraftment, poor localization, and a lack of delivery strategies that are both effective and minimally invasive. To address these challenges, we developed injected, self-assembled, image-guided tissue ensembles (INSITE), an injectable platform composed of primary human hepatocytes (PHHs) and hydrogel microspheres that assemble in situ into supportive, vascularizable scaffolds following image-guided delivery.
Ultrasound-guided delivery into an ectopic site enabled precise graft localization, persistent noninvasive imaging, and vascular integration in vivo. Hepatocytes remained confined within these scaffolds and maintained long-term functional activity. Furthermore, tuning material properties allowed control over scaffold remodeling and vascular recruitment to enhance graft function. By integrating image-guided delivery with a modular scaffold, INSITE establishes a clinically compatible strategy for advancing minimally invasive cell therapies.
Link: https://doi.org/10.1016/j.celbio.2026.100378
View the full article at FightAging
